Patents Examined by Quang Nguyen
  • Patent number: 11208664
    Abstract: The present disclosure relates, in some aspects, to bile acid sensors.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: December 28, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Christopher Voigt, Mao Taketani
  • Patent number: 11204305
    Abstract: The invention refers to a composition for the fixation of histological preparations, comprising a solution of glyoxal, wherefrom acids, normally present in the commercially available glyoxal, have been removed. The composition of the invention provides an optimal fixative for the preservation of structure, antigenic components and nucleic acids in tissues. The acid-free glyoxal has limited toxicity, is not considered as a carcinogenic agent and represents a valid alternative to formalin for the fixation of tissues and cells.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 21, 2021
    Assignee: ADDAX BIOSCIENCES S.R.L.
    Inventor: Giovanni Bussolati
  • Patent number: 11180610
    Abstract: The present invention relates to the purification of poloxamers to be used as cell culture media additives. Activated carbon can be used to remove hydrophobic high molecular weight components which reduce the efficacy of poloxamers as cell culture additives.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: November 23, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Anja Licht, Almut Rapp, Joerg Von Hagen
  • Patent number: 11136557
    Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Melissa A. Kotterman, Bum-Yeol Hwang, James T. Koerber
  • Patent number: 11124804
    Abstract: The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use. In some embodiments, a multimeric coding nucleic acid (MCNA) comprises two or more encoding polynucleotides linked via 3? ends such that the multimeric coding nucleic acid compound comprises two or more 5? ends.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 21, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
  • Patent number: 11110138
    Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 7, 2021
    Assignee: CELVERUM INC.
    Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
  • Patent number: 11098313
    Abstract: The present invention relates to the production and use of covalently closed circular (ccc) recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 24, 2021
    Assignee: NATURE TECHNOLOGY CORPORATION
    Inventor: James A. Williams
  • Patent number: 11033638
    Abstract: The invention relates to a viral expression construct and related viral vector and composition and to their use wherein the construct and vector comprise elements a) and b): a) a nucleotide sequence encoding an insulin operably linked to a first promoter, b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter and the viral expression construct and related viral vector comprise at least one of elements c), d) and e): c) the first and the second promoters are positioned in reverse orientation within the expression construct, d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and e) the first promoter is a CMV promoter, preferably a mini CMV promoter.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: June 15, 2021
    Assignee: UNIVERSITÄT AUTONOMA DE BARCELONA
    Inventors: Fatima Bosch Tubert, Miguel Garcia Martinez, Veronica Jiménez Cenzano, Virginia Haurigot Mendonça
  • Patent number: 11021696
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 1, 2021
    Assignees: Children's Medical Center Corporation, Sangamo Therapeutics, Inc.
    Inventors: Stuart H. Orkin, Andreas Reik, Fyodor Urnov
  • Patent number: 11001860
    Abstract: The present invention provides a poxvirus-derived promoter, a vector comprising the same, a method for expressing a transgene using the promoter, and use of the vector in the prevention or treatment of a disease. A promoter according to the present invention can be used for induction of strong expression of a transgene.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 11, 2021
    Assignee: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong Kim, Minjung Kim, Hwanjun Choi
  • Patent number: 10994027
    Abstract: Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5? to 3? orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 4, 2021
    Assignee: Provecs Medical GmbH
    Inventors: Frank Schnieders, Andrea Miegel, Carolin Biermann-Fleischhauer
  • Patent number: 10973930
    Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 13, 2021
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Ziyuan Guo, Zheng Wu, Zifei Pei, Yuchen Chen
  • Patent number: 10953109
    Abstract: The present invention relates to the field of biotechnology, in particular to application of a GPR45 gene. The present invention discloses, for the first time, a correlation between GPR45 and obesity and also discloses that obesity may be caused if the GPR45 gene is knocked out or the expression of the GPR45 gene is reduced. Moreover, an obese mouse model is established by adopting a method of blocking the expression of the GPR45 gene for the first time, which is more similar to the mechanism underlying the obesity of human, is thus an ideal model for obesity basis and clinical application researches and can be well applied in screening of drugs for treating obesity.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 23, 2021
    Inventors: Xiaohui Wu, Tian Xu, Min Han, Jing Cui, Tongruei Li
  • Patent number: 10906984
    Abstract: An object of the present invention is to provide CAR-expressing T cells that coexpress a chimeric antigen receptor (CAR) and a T cell immune function-enhancing factor and have a high immunity-inducing effect and antitumor activity, and to provide a CAR expression vector for the preparation of the CAR-expressing T cells. A CAR expression vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR) and a nucleic acid encoding a T cell immune function-enhancing factor, wherein the nucleic acid encoding an immune function-enhancing factor is a nucleic acid encoding interleukin-7 and a nucleic acid encoding CCL19, a nucleic acid encoding a dominant negative mutant of SHP-1, or a nucleic acid encoding a dominant negative mutant of SHP-2, or a CAR-expressing T cell introduced with the CAR expression vector are prepared.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: February 2, 2021
    Assignee: YAMAGUCHI UNIVERSITY
    Inventors: Koji Tamada, Yukimi Sakoda, Keishi Adachi
  • Patent number: 10889822
    Abstract: The invention relates to a method for transcription and expression using a nucleic acid construct which is characterized by the presence of a promoter followed by an intronic promoter. The invention further relates to the nucleic acid construct, an expression vector and a cell comprising the construct, and its use. The invention also relates to methods for transcription and optionally expression using a nucleotide sequence. The invention further relates to the nucleotide sequence and a construct, expression vector and cell comprising the nucleotide sequence, and its use.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: January 12, 2021
    Inventors: Maurice Wilhelmus van der Heijden, Bart Marinus Engels
  • Patent number: 10865242
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 15, 2020
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Patent number: 10851379
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 1, 2020
    Assignee: BAYER ANIMAL HEALTH GMBH
    Inventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Patent number: 10844388
    Abstract: A eukaryotic replicative pUC-free minicircle expression vector is provided. The eukaryotic replicative pUC-free minicircle expression vector includes a pUC-free eukaryotic region sequence encoding a transgene of interest and comprising 5? and 3? ends and ii) a pUC-free spacer region of less than 500 basepairs in length linking the 5? and 3? ends of the eukaryotic region sequences and comprising a bacterial R6K replication origin having at least 95% sequence identity to SEQ ID NO: 11 or SEQ ID NO: 12 and a RNA selectable marker, the RNA selectable marker being an RNA-IN regulating RNA-OUT functional variant having at least 95% sequence identity to SEQ ID NO:20 or SEQ ID NO:22.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: November 24, 2020
    Assignee: Nature Technology Corporation
    Inventor: James A. Williams
  • Patent number: 10829785
    Abstract: Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 10, 2020
    Assignee: Trizell Limited
    Inventors: Hanna P. Lesch, Kari J. Airenne, Seppo Yla-Herttuala
  • Patent number: 10828376
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: November 10, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Brigit E. Riley, Gary K. Lee